Skip to main content

Drug Interactions between Anturane and aspirin / pravastatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

aspirin sulfinpyrazone

Applies to: aspirin / pravastatin and Anturane (sulfinpyrazone)

GENERALLY AVOID: Salicylates may antagonize the uricosuric effect of sulfinpyrazone. The exact mechanism of interaction is unknown, although therapeutic doses of aspirin have been shown to increase plasma clearance of sulfinpyrazone. In one study, acute pretreatment with aspirin (325 mg four times a day for 24 hours) resulted in increased plasma clearance of a single 400 mg dose of sulfinpyrazone in 5 of 6 subjects by 12% to 27% relative to administration of sulfinpyrazone alone. When sulfinpyrazone 200 mg and aspirin 325 mg were coadministered four times a day for one week, plasma clearance of sulfinpyrazone increased up to 229%. The investigators theorized that aspirin may displace sulfinpyrazone from plasma protein binding sites, resulting in a redistribution of sulfinpyrazone into peripheral compartments and increased amount of free drug for hepatic metabolism. In vitro data also suggest that sulfinpyrazone may interfere with the irreversible effects of aspirin (especially low doses) on platelets, although the clinical significance is unknown.

MANAGEMENT: Salicylates should not be used during sulfinpyrazone therapy for gouty arthritis. However, occasional small doses of salicylates are not expected to interact significantly.

References

  1. Buchanan MR, Endrenyi L, Giles AR, Rosenfeld J (1983) "The effect of aspirin on the pharmacokinetics of sulfinpyrazone in man." Thromb Res Suppl, 4:, p. 145-52
  2. (2001) "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals
  3. Ali M, McDonald JW (1979) "Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity." Prostaglandins Med, 3, p. 327-32

Switch to consumer interaction data

Drug and food interactions

Moderate

aspirin food

Applies to: aspirin / pravastatin

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Moderate

pravastatin food

Applies to: aspirin / pravastatin

MONITOR: Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury. Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury. Active liver disease or unexplained transaminase elevations are contraindications to statin use.

MANAGEMENT: Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.

References

  1. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  2. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  3. (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
  4. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  5. (2002) "Product Information. Altocor (lovastatin)." Andrx Pharmaceuticals
  6. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
  7. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  8. Cerner Multum, Inc. "Australian Product Information."
  9. (2010) "Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)
View all 9 references

Switch to consumer interaction data

Minor

aspirin food

Applies to: aspirin / pravastatin

One study has reported that coadministration of caffeine and aspirin lead to a 25% increase in the rate of appearance and 17% increase in maximum concentration of salicylate in the plasma. A significantly higher area under the plasma concentration time curve of salicylate was also reported when both drugs were administered together. The exact mechanism of this interaction has not been specified. Physicians and patients should be aware that coadministration of aspirin and caffeine may lead to higher salicylate levels faster.

References

  1. Yoovathaworn KC, Sriwatanakul K, Thithapandha A (1986) "Influence of caffeine on aspirin pharmacokinetics." Eur J Drug Metab Pharmacokinet, 11, p. 71-6

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer